Statement from Medtronic Regarding FDA Circulatory System Devices Panel

Rapid Unit Sales of Medical Masks to Account for Incremental Revenues in the Global Market Through the COVID-19 Crisis Period

Medical facilities are highly dependent on the use of medical masks during surgeries. The availability of different versions of mask for different applications across different end-users, such as ambulatory surgical centre’s, hospitals, dental settings, etc., are expected to fuel the growth of the medical mask market throughout the forecast period.

Proximie Raises $38m Series B Funding To Accelerate Its Expansion in U.S. and European Markets

F-Prime Capital led financing, joined by Questa Capital, Eight Roads, and Maverick Ventures

June 21, 2019

Statement from Medtronic was issued today regarding the U.S. Food and Drug Administration Circulatory System Devices Panel of the Medical Devices Advisory Committee on paclitaxel-coated therapies in patients with peripheral artery disease in the superficial femoropopliteal artery.

Medtronic reports: Patient safety is our top priority – and has been since our company’s founding more than 60 years ago. These panel deliberations are critically important as the Food and Drug Administration (FDA), societies, physicians, and industry consider and address the recent questions around the safety of paclitaxel devices in peripheral arterial disease (PAD) above-the-knee. As an industry leader, we take our responsibility to patients and physicians very seriously and look forward to further collaboration on a response to the panel’s recommended next steps.

The Medtronic presentation included the independent, patient-level analysis from our two randomized controlled trials (RCTs)-IN.PACT SFA and IN.PACT Japan. This analysis also accounts for vital status data on 97 percent of patients from our RCTs, representing the highest rate obtained across all industry clinical data presented at the panel. Results demonstrate:

  • No drug-related mechanism for observed transient mortality signal
  • No observed dose relationship with mortality
  • No pattern of adverse events or cause of death to suggest unifying mechanism
  • No relatedness between deaths and paclitaxel, as adjudicated by a newly convened independent Clinical Events Committee (CEC) with paclitaxel toxicity expertise

Additionally, Peter A. Schneider, M.D., professor of Surgery, Division of Vascular & Endovascular Surgery, University of California San Francisco and principal investigator of the IN.PACT SFA trial, presented the clinical benefit of IN.PACT Admiral. In the IN.PACT SFA trial, three out of four DCB patients remained intervention-free through five years, and for DCB patients who required a repeat procedure, the time to reintervention was prolonged for more than two years. Medtronic remains confident that the IN.PACT Admiral benefit-risk profile is positive and supports IN.PACT Admiral DCB as a first-line strategy for the treatment of PAD.

The panel presentations and deliberations addressed a wide range of considerations related to paclitaxel drug-coated balloons (DCB) and drug-eluting stents (DES). Laura Mauri, M.D., vice president, Global Clinical Research & Analytics, Medtronic also presented alongside Dan Clair, M.D., chair of the Department of Surgery for the University of South Carolina (USC) and the Palmetto Health-USC Medical Group and Eric A. Secemsky, M.D., MSc, RPVI, FACC, FVSM, Beth Israel Deaconess Medical Center, Harvard Medical as part of an unprecedented pan-industry presentation.

spot_img

DON'T MISS

Related Articles